SCHEMBL18632524

SCHEMBL18632524

O=c1[nH]nc2cccc(-c3ccccc3)n12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 5/20 0.47
PDE3A Q14432 5/20 0.47
PDE1A P54750 4/20 0.47
PDE1B Q01064 4/20 0.47
PDE1C Q14123 4/20 0.47
PDE5A O76074 4/20 0.47
GRM2 Q14416 1/20 0.42
CHEK1 O14757 4/20 0.42
CDK8 P49336 3/20 0.41
DYRK1A Q13627 3/20 0.41
DYRK1B Q9Y463 3/20 0.41
MAP2K1 Q02750 3/20 0.41
MAP4K4 O95819 2/20 0.41
PRKACA P17612 2/20 0.41
KDR P35968 2/20 0.41
MAP4K2 Q12851 2/20 0.41
ROCK1 Q13464 2/20 0.41
AURKB Q96GD4 2/20 0.41
CSF1R P07333 1/20 0.41
ACVR1 Q04771 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13114978 0.82 NOTUM (0.43) GRM2CHEK1NOTUMCYP1A2
SCHEMBL18632522 0.78 CHEK1 (0.38) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL13114979 0.73 CHEK1 (0.43) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL18632532 0.73 CHEK1 (0.43) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL11088652 0.73 CHEK1 (0.49) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL17403218 0.72 CHEK1 (0.42) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL20996080 0.72 CHEK1 (0.39) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL18632515 0.72 CHEK1 (0.39) PDE3BPDE3APDE1APDE1BPDE1C
SCHEMBL14492478 0.72 CHEK1 (0.52) GRM2CHEK1CDK8DYRK1ADYRK1B
SCHEMBL19646489 0.69 CHEK1 (0.42) PDE3BPDE3APDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017046318-A1 TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2017-03-23 WO disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease OAT, XDH, MAPT PDE3B 1028/4885PDE3A 701/4885PDE1A 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.